# US 8,784,845 B2 · Selective chemokine modulation > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,784,845 B2 - Document ID: US8784845B2 - Status: Granted - Kind: B2 - Application number: 12/441,000 - Filed: 2007-09-11 - Published: 2010-08-12 - Granted: 2014-07-22 - Earliest claimed: 2006-09-12 - Assignees: Prophy Med AB - Applicants: Lars Bruce; Staale Petter Lyngstadaas - Inventors: Lars Bruce; Staale Petter Lyngstadaas - Web page: https://patentgrep.com/patent/US8784845B2 ## CPC - A61M 1/38: Removing constituents from donor blood and {storing or} returning remainder to body {, e.g. for transfusion} - A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)} - A61K 33/24: Heavy metals; Compounds thereof - A61M 1/3679: {by absorption (A61M1/3675 takes precedence)} - A61P 17/00: Drugs for dermatological disorders - A61P 19/02: for joint disorders, e.g. arthritis, arthrosis - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61P 31/12: Antivirals - A61P 37/00: Drugs for immunological or allergic disorders - A61P 37/02: Immunomodulators - A61P 37/04: Immunostimulants - A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection - B01J 20/02: comprising inorganic material - B01J 20/06: comprising oxides or hydroxides of metals not provided for in group B01J20/04 - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract The present invention teaches the use of a metal or an oxide of a metal having a capability of reducing the amount of the chemokine IP-IO in a sample and/or reducing the production of IP-IO in cells. The metal is a metal of group 4 or 5 in the periodic table of the elements and preferably titanium. These metals and metal oxides can selectively bind IP-IO to its surface to thereby scavenge IP-IO from the surrounding medium. In addition, a metal-cell contact induces a reduction in the production of IP-IO from IP-IO producing cells. The metals and metal oxides of the present invention can therefore be used for treating and/or preventing medical conditions characterized by adverse IP-IO expression, such as inflammatory reactions. ## Claims ### Claim 1 A method of reducing 10 kDa interferon-γ inducible protein, IP-10, in an extracted body fluid of a subject suffering from a disease characterized by adverse expression and/or release of IP-10, the method comprising: extracting body fluid from the subject; contacting said body fluid ex vivo with a metal selected from the group consisting of titanium, zirconium, hafnium, niobium and tantalum, or an oxide of said metal, wherein IP-10 in the body fluid binds to the metal or metal oxide; removing the metal or oxide of the metal to which IP-10 is bound from the body fluid; and after said removal, returning said body fluid to said subject. ### Claim 2 (depends on 1) The method according to claim 1, wherein said body fluid is selected from the group consisting of blood, blood plasma, lymph fluid, cerebrospinal fluid, ascites and synovial fluid. ### Claim 3 (depends on 1) The method according to claim 1, wherein said disease is selected from the group consisting of an infectious disease, an adverse inflammatory response and a host versus graft disease characterized by adverse expression and/or release of IP-10 in said subject. ### Claim 4 (depends on 3) The method according to claim 3, wherein said infectious disease is a viral infectious disease. ### Claim 5 (depends on 3) The method according to claim 3, wherein said adverse inflammatory response is an autoimmune disease. ### Claim 6 (depends on 3) The method according to claim 3, wherein said adverse inflammatory response is an inflammatory disease of the gastro intestinal tract of said subject. ### Claim 7 (depends on 3) The method according to claim 3, wherein said adverse inflammatory response is an inflammatory skin disease. ### Claim 8 (depends on 3) The method according to claim 3, wherein said host versus graft disease is an acute graft rejection. ### Claim 9 (depends on 1) The method according to claim 1, wherein said disease is a foreign body reaction. ### Claim 10 (depends on 1) The method according to claim 1, wherein said metal is selected from the group consisting of titanium and tantalum. ### Claim 11 (depends on 1) The method according to claim 1, wherein said oxide of said metal is selected from the group consisting of an oxide of titanium and an oxide of tantalum. ### Claim 12 (depends on 11) The method according to claim 11, wherein said oxide of titanium is a titanium dioxide. ### Claim 13 (depends on 12) The method according to claim 12, wherein said titanium dioxide is a titanium dioxide of rutile form or a mixture of rutile form and anatase form. ### Claim 14 (depends on 1) The method according to claim 1, wherein said metal or said metal oxide is in the form of granules or particles having a total porosity of at least about 50%. ### Claim 15 (depends on 1) The method according to claim 1, wherein said metal or said metal oxide is in the form of granules or particles having a total surface area of at least about 0.01 m2/g. ### Claim 16 (depends on 1) The method according to claim 1, wherein said metal or said metal oxide is in the form of metal or metal oxide particles having an average powder particle diameter below 100 μm. ### Claim 17 (depends on 1) The method according to claim 1, wherein said body fluid is contacted ex vivo with said metal or said oxide of said metal in a body fluid purifying arrangement comprising: a purifying chamber having a fluid input and a fluid output and comprising particles made of said metal or said oxide of said metal; and at least one filter arranged in connection with the fluid output for preventing said particles from leaving said purifying chamber. ### Claim 18 (depends on 1) The method according to claim 1, wherein IP-10-producing cells in the body fluid bind to the metal or metal oxide. ### Claim 19 (depends on 18) The method according to claim 18, wherein the IP-10-producing cells comprise neutrophils and monocytes.